ARTICLE / CLIENT ALERT
Justices Knowingly Interpret BIPA to Include ‘Annihilative,’ ‘Punitive’ and ‘Crippling Liability’ for Illinois Businesses
February 17, 2023
Read time: 5 min
On February 17, 2023, the Illinois Supreme Court ruled in Cothron v. White Castle System, Inc., 2023 IL 128004, that claims accrue under the Illinois Biometric Information Privacy Act (BIPA) each time data is collected and disclosed rather than accrual occurring upon the first registration, collection or disclosure of biometric information and identifiers. This ruling will have a major impact on all future BIPA cases and will lead to negative implications for Illinois employers and other companies that collect biometric information about Illinois residents. As the dissent put it, this decision could have a “crippling,” “punitive” and “annihilative” impact on Illinois businesses.
BIPA requires informed consent before the collection or disclosure of an individual’s biometric information through, for example, a time clock or electronic lock. Specifically, section 15(b) of the Act provides that a private entity may not “collect, capture, purchase, receive through trade, or otherwise obtain” a person’s biometric data without first providing notice to and receiving consent from the person. Section 15(d) provides that a private entity may not “disclose, redisclose, or otherwise disseminate” biometric data without consent.
The Cothron Court was asked to answer the certified question from the US Court of Appeals for the 7th Circuit whether “section 15(b) and 15(d) claims accrue each time a private entity scans a person’s biometric identifier and each time a private entity transmits such a scan to a third party, respectively, or only upon the first scan and first transmission?” White Castle, supported by numerous amici, argued that only the first scan or disclosure should trigger a new claim under BIPA, while Cothron argued that each scan by a putative class member constitutes a new BIPA violation (that is, every clock in or clock out scan every time an employee scans into work could be a separate accrual or violation of BIPA). Indeed, even well-known plaintiffs’ firms were on the record in support of White Castle’s position.
Yet, continuing the axiom that if a BIPA ruling can go against defendants it will, in its 4-3 opinion, the Cothron Court held “that a separate claim accrues under the Act each time a private entity scans or transmits an individual’s biometric identifier or information in violation of section 15(b) or 15(d).” Essentially, this holding means that every collection and disclosure of biometric data between the same two parties (e.g., every time an employee scans in for a shift using his fingerprint) constitutes a new BIPA violation.
White Castle estimated that if Cothron can bring claims on behalf of as many as 9,500 current and former White Castle employees, where employees potentially scan their fingerprints multiple times per shift, damages in this action may exceed $17 billion. The court was cognizant of the extreme and absurd damages that could result in violations of BIPA but stated that it was not the court’s place to rewrite the statute simply because damages could be wildly excessive.
The court agreed with the 7th Circuit that private entities “would have ‘little incentive to course correct and comply if subsequent violations carry no legal consequences.’” (citing Cothron v. White Castle System, Inc., 20 F.4th 1156, 1165 (7th Cir. 2021)). While the majority “recognized the potential for significant damages awards under the Act,” it reasoned that “the legislature intended to subject private entities who fail to follow the statute’s requirements to substantial potential liability.”
Justice David Overstreet, writing for the dissent, disagreed with the majority opinion because it could “not be reconciled with the plain language of the statute,” the purpose behind BIPA, or case law. Justice Overstreet reasoned that a claim should accrue only upon the first scan, collection or transmission of biometric information and data. The dissent was also concerned with the decision leading to absurd results not intended by the legislature in passing BIPA.
The dissent’s reasoning was sound: Because an entity can obtain a person’s biometrics only once, the subsequent scans are not obtaining or collecting a scan – the entity already had the scan and nothing new was collected. According to the dissent, “The majority acknowledges that, in construing the Act as it has, the consequences may be harsh, unjust, absurd, or otherwise unwise.”
Finally, the dissent noted that “imposing punitive, crippling liability on businesses could not have been a goal of the Act, nor did the legislature intend to impose damages wildly exceeding any remotely reasonable estimate of harm.” This is the exact type of practical consideration that the majority “brushes . . . aside” when saying the legislature is the best entity to address excessive damages. The dissent may serve prophetic, however, because defendants will likely attack these excessive damages and absurd this interpretation of BIPA to argue that it is unconstitutional.
This ruling is likely to have a significant impact on BIPA litigations and resolutions going forward. It is hard to imagine that “crippling liability” is what the Illinois legislature had in mind when enacting BIPA. And it seems likely that the pathway forward will be new assaults against BIPA’s constitutionality, and, hopefully, the Illinois legislature will finally recognize the immediate need to amend BIPA.

DOJ Signals Heightened Scrutiny on Information Exchanges and Competitor Collaborations
ARTICLE / CLIENT ALERT
DOJ Signals Heightened Scrutiny on Information Exchanges and Competitor Collaborations
February 15, 2023
Read time: 7 min
WHAT HAPPENED
On February 3, 2023, the US Department of Justice’s (DOJ) Antitrust Division announced the withdrawal of three policy statements related to antitrust enforcement in healthcare. Although the withdrawn statements focus on healthcare, DOJ’s decision to withdraw these statements will have broad impacts across industries.
The three policy statements, issued in 1993, 1996, and 2011, relate to competitor collaboration and information sharing, and established “safety zones” of activities shielded from antitrust scrutiny. The 1996 Statements of Antitrust Enforcement in Health Care (1996 Statements) were revised and expanded upon the 1993 Statements. Though ostensibly related to healthcare, the guidance has been relied upon by all industries and understood to cover all manner of competitively sensitive information. Two of the safety zones most often relied on by companies relate to competitor exchanges of price and cost information, and competitor joint purchasing arrangements.
Information Exchanges
The safety zone on information exchanges (Statement 6 of the 1996 Statements) stated that, in general, the agencies would not challenge an exchange of price or cost information (e.g., employee compensation) if the following three conditions were met:
- The exchange is managed by a third party (e.g., a trade association or consultant).
- The information is more than three months old.
- The exchange has five or more participants contributing data, and no individual participant’s data represents more than 25% of any statistic; and no individual participant’s data can be identified.
Companies have relied on this safety zone in conducting surveys and benchmarking related to pricing, supply costs, and salaries. These surveys have served as critical compliance tools. Organizations exempt from federal income tax often use surveys to demonstrate fair market value compensation to safeguard against claims of private inurement and private benefit. Similarly, healthcare companies routinely use benchmarking studies to demonstrate fair market value compensation for compliance with fraud and abuse laws.
Group Purchasing Organizations
The safety zone on joint purchasing arrangements (Statement 7 of the 1996 Statements) stated that, in general, the agencies would not challenge joint purchasing arrangements (e.g., group purchasing organizations (GPOs)) if the following two conditions were met:
- The purchases account for less than 35% of the total sales of the purchased product or service.
- The cost of the products or services purchased jointly accounts for less than 20% of the participants’ revenues.
DOJ cited changes in the healthcare landscape as the rationale for withdrawing these policy statements, specifically indicating that the statements were “overly permissive” on information sharing. In a speech the day before DOJ’s announcement, Principal Deputy Assistant Attorney General (DAAG) Doha Mekki stated that the safety zone factors “do not consider the realities of a transformed industry” and “understate the antitrust risks of competitors sharing competitively sensitive information.” DAAG Mekki explained that:
- Information exchanges managed by third parties can have the same anticompetitive effects—and the use of a third party enhances anticompetitive effects.
- New algorithms and AI learning increase the competitive value of historical information (more than three months old) for certain products and services.
- Five or more participants do not guarantee that such an information exchange will not harm competition, especially when the participants exchanging the information collectively have a large share in the relevant market.
Thus, according to DAAG Mekki, “maintaining the safety zones would be like developing specifications for audio cassette tapes and applying them to digital streaming.” DOJ is concerned that technological advances may allow companies and third-party entities greater capabilities to reverse engineer certain kinds of information in ways that facilitate coordination (e.g., using AI learning or complex algorithms to predict individual participants’ future behavior based on historical data, or disaggregate or unblind an individual participant’s data).
ACOs/CINs/IPAs
Statements 8 and 9 of the 1996 Statements addressed physician network joint ventures and multiprovider networks, commonly known as independent practice associations (IPAs) and clinically integrated networks (CINs). These statements set forth widely adopted concepts of substantial financial risk sharing and clinical integration programs that, where sufficient, served as a basis for competing providers to jointly contract with payors under the more favorable rule of reason standard of review. The 2011 Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program (2011 ACO Statement) provided that accountable care organizations (ACOs) participating in the Medicare Shared Savings Program (MSSP) would be afforded rule of reason treatment if, in the commercial market, the ACO used the same governance and leadership structure and clinical and administrative processes as for MSSP participation. This was a significant benefit to hybrid ACOs/CINs, as it eliminated the risk of commercial activities being treated as a per se unlawful price-fixing or market allocation agreements among competitors. As a result, many health systems and physician groups relied on the 2011 ACO Statement. This assurance no longer exists.
WHAT THIS MEANS
The policy statements and the safety zones never had the force of law, but their withdrawal leads to greater uncertainty for companies involved in information exchanges and other competitor collaborations. Companies routinely rely on third-party studies of historical data from several market participants to evaluate how to price their products and services and ensure they are setting competitive prices, paying competitive prices for inputs and supplies, and offering competitive compensation and benefits to their employees. The withdrawal of the statements removes clear guidance on how to do this lawfully. Companies would be wise to review their existing information exchanges, with an emphasis on ensuring that participation in information exchanges does not facilitate coordination because the information being exchanged can be disaggregated or unblinded to identify specific participants’ data. The agencies are increasingly focused on competition issues related to employee compensation and hiring (see the Federal Trade Commission’s (FTC) proposed rule banning noncompete agreements, discussed in our Antitrust Alert blog post, “FTC proposes rule banning noncompete agreements”).
Despite DOJ’s action, companies can still exchange information—even with competitors. DOJ, however, is seeking to insert uncertainty around what kinds of exchanges are always reasonable. Our view is that going forward companies should follow the FTC’s 2014 advice shared in a blog post that advised: “let reason be your guide.” That blog cited the FTC and DOJ’s 2000 Antitrust Guidelines for Collaborations Among Competitors—which have not been withdrawn—which explained that reasonableness “depends on the nature of information” shared:
- The sharing of information on price, output, costs, or strategic plans is more likely to raise competitive concerns than the sharing of less sensitive information.
- The sharing of information on current and future plans is more likely to raise competitive concerns than the sharing of historical information.
- The sharing of individual company data is more likely to raise concern than the sharing of aggregated data that does identify individual companies.
In our view, the path forward is to use the withdrawn “safety zones” as a starting point for assessing whether the information-sharing protocols are reasonable in light of potential government concerns. Companies, therefore, with the assistance of antitrust counsel, should take time to reassess their information-sharing protocols to consider the reasonableness of those protocols considering the nature of the information shared and the business purpose of that arrangement. Heightened focus should be given to the use of information shared or received and how it might impact pricing or compensation decisions.

Bulletin Concurrence VI
ARTICLE
Bulletin Concurrence VI
February 13, 2023
Read time: 2 min
New year, new Bulletin Concurrence !
We are delighted to share the sixth Bulletin Concurrence which aims to keep you up to date with the key developments in competition law over the last quarter of 2022.
Read the full Bulletin (in French) here

New York Proposes Regulatory Review of Physician Practice Transactions
ARTICLE / CLIENT ALERT
New York Proposes Regulatory Review of Physician Practice Transactions
February 14, 2023
Read time: 8 min
On February 1, 2023, New York Governor Kathy Hochul announced the FY 2024 New York State Executive Budget, which included a proposal for the New York Department of Health (the Department) to review and approve material transactions involving physician practices and physician practice management organizations. If the proposal is finalized, it will create a potentially lengthy regulatory approval process for common transactions in New York State.
1. Review of “Material Transactions”
At its core, the legislation requires a “health care entity” to obtain approval from the Department before consummating a “material transaction.” The definition of “health care entity” includes both physician practices and management services organizations among other entities, although it excludes a number of other types of healthcare providers already subject to the Certificate of Need process (for example, ambulatory surgery centers (ASCs) and diagnostic and treatment centers (D&TCs), including end-stage renal disease dialysis clinics). The definition of a “material transaction” includes a broad range of transactions:
(i) A merger with a healthcare entity;
(ii) An acquisition of one or more healthcare entities, including but not limited to the assignment, sale or other conveyance of assets, voting securities, membership or partnership interest or the transfer of control;
(iii) An affiliation or contract formed between a healthcare entity and another person; or
(iv) The formation of a partnership, joint venture, accountable care organization, parent organization or management services organization for the purpose of administering contracts with health plans, third-party administrators, pharmacy benefit managers or healthcare providers as prescribed by the commissioner by regulation.
“Control” is presumed to exist if a person directly or indirectly owns, controls or holds the power to vote 10 percent (10%) or more of the voting securities of a healthcare entity.
The Department’s review would assess material transactions’ “impact on cost, quality, access, health equity and competition in the healthcare service market.” The Department may consider the following factors in its review:
(a) Whether the “potential positive impacts” of the transaction outweigh the negative ones with respect to patient costs, access to services, health equity and health outcomes;
(b) Whether there will be anticompetitive effects;
(c) The financial condition of the parties to the transaction;
(d) The character and competence of the parties;
(e) The source of the funds or assets for the transaction;
(f) The fairness of any exchange or other consideration; and
(g) Any other relevant information to determine the impact of the material transaction.
2. Notices and Consents
Healthcare entities contemplating material transactions would need to submit notice of a material transaction at least 30 days pre-closing. Although the Department would be required to decide on the request within 30 days, the Department could withhold approval in order “to conduct a thorough examination and complete analysis of whether the transaction is consistent with” state policy.
During its review, the Department would be required to publicly post the proposed transaction for notice and comment. Such public notice would include:
(a) A summary of the proposed transaction;
(b) An explanation of the groups or individuals likely to be impacted by the transaction;
(c) Information about services currently provided by the healthcare entity, commitments by the healthcare entity to continue such services and any services that will be reduced or eliminated; and
(d) Details about how to submit comments in a format that is easy to find and easy to read.
3. Penalties
The legislation permits the Department to impose civil penalties of up to $10,000 per day for a violation of the requirements.
4. Timeline
The bill must still pass both the New York Senate and Assembly before the Governor can either sign or veto it. The timeline for inclusion in the budget is dictated by the budget process. The New York State Budget is set to be passed by April 1, 2023. If passed with the budget as proposed, the proposed law would apply to material transactions closing on or after April 1, 2024.
New York State budgets tend to change between proposal and finalization. The budgets for the years 2022-2023, 2021-2022, 2020-2021, 2019-2020 and 2018-2019 were finalized after four rounds of changes. The 2017-2018 budget is the least edited in recent memory, with the proposal finalized after three rounds of changes.
5. Analysis and Takeaways
The “purpose and intent” of the proposed law focuses on recent trends in patient care shifting from the hospital setting to the physician office setting. The legislation cites a general lack of regulatory oversight of investor-backed physician practices particularly as these entities “increasingly take on the characteristics associated with diagnostic and treatment centers. . . or . . . assume more risk from managed care organizations and licensed insurers.” In addition, the legislation notes that change in control transactions of these organizations are not currently subject to state oversight, limiting the state’s ability to “track or monitor the impact of these transactions on cost, quality, access, equity, and competition.”
The legislation speculates that this trend may negatively impact patient care, cost and access, and it asserts that it also undermines hospital financial sustainability. Interestingly, the proposed law states that the concentration of investor-backed physician practices is a “significant contributor” to healthcare cost inflation, although it does not explain how the transition from the hospital ambulatory setting to the physician office setting results in increased costs to patients. Indeed, the Division has historically taken the position that moving avoidable institutional care to community and outpatient-based care can lead to better care, better health and lower costs. Nonetheless, our ongoing discussions have suggested that the proposed law is primarily motivated by reimbursement and financial sustainability considerations for those health care entities exempted from the proposed law.
The proposed law was included in the Executive Budget, and it will be subject to extensive review and scrutiny before the budget is finalized. Since the release of the proposed legislation, there has been a sense that the broad implications of the proposed legislation may not yet have been fully vetted, particularly where this legislation has never been proposed in the New York Senate or Assembly or otherwise subject to public comment. Historically, the Executive Budget has been subject to multiple revisions before finalizing, and many are suggesting that the proposal be removed from the budget and transitioned to the Commission on the Future of Health Care, the committee that the Governor is proposing study the future of healthcare provision in New York State.
The proposed law’s requirements are broad and would likely require the promulgation of regulations to confine its scope if it were advanced through the legislative and regulatory processes. The process for proposing and finalizing regulations in New York is lengthy and subject to public comment, making the April 1, 2024, target implementation date unlikely even if the law were to be passed with the State Budget in April.
Given the legislation’s references to the Certificate of Need and other related regulatory approval processes, we might expect the legislation or promulgating regulations to gravitate towards these existing approval structures and their definitions, as relating to reviewable changes of ownership and management services agreements. It is noteworthy, however, that the proposed legislation would not authorize the Public Health and Health Planning Council (PHHPC) to approve material transactions (PHHPC is authorized to approve various other healthcare transactions, including changes in the ownership of hospitals, ASCs and D&TCs). While the absence of PHHPC review may offer a relatively more streamlined process for review under the proposed legislation, the subject matter to be considered is vast and would consume significant resources to prepare and review.
The proposed “character and competence” review could be quite invasive, and ownership disclosure requirements for management services organization may raise significant challenges given the complexity of most investor-backed management services organizations. However, whether the “character and competence” review would be limited to the parties or also include their direct and indirect owners is unspecified in the proposed legislation. While the 30-day timeframe appears manageable, this timeframe may be extended by the Department upon simple notice to accommodate a more extensive review. A protracted review process may result in delays to ordinary course physician transactions and significantly affect the timing of transactions in New York.
While there is a chance that the proposal will not be finalized as part of the FY 2024 budget (and some would argue a significant chance), the proposal will certainly be subject to continued discussion and potential future permutations. Notably, a number of other states have implemented notice requirements for certain physician practice transactions. If New York does take action to review material transactions involving physician practices and administrative services organizations, it will be critical to ensure existing and future investment strategies are structured to navigate the changed landscape.

IRS Issues Initial Low-Income ITC Bonus Guidance
ARTICLE / CLIENT ALERT
IRS Issues Initial Low-Income ITC Bonus Guidance
February 14, 2023
Read time: 7 min
The Internal Revenue Service (IRS) has released initial guidance on the low-income adder to the investment tax credit (ITC) under Section 48(e) (Low-Income Bonus). The guidance, released in IRS Notice 2023-17 (Notice), provides limited clarification regarding the Low-Income Bonus and leaves significant questions unanswered. Accordingly, most taxpayers will likely require further guidance on the application and approval process before transacting around the Low-Income Bonus.
The most noteworthy takeaways from the guidance include the following:
- How the 1.8-gigawatt (GW) capacity limitation will be allocated among four subcategories
- The IRS has not yet determined how it will allocate any one category in the event applicants exceed the allocated capacity limitation
- Confirmation that further substantive guidance is forthcoming
- Projects placed in service before approval by the IRS are not eligible for the Low-Income Bonus
- Confirmation that the IRS will administer applications through a phased timeline in Q3 2023 and thereafter.
DETAILS OF THE NOTICE
The Low-Income Bonus was added to Section 48 last year pursuant to the enactment of the Inflation Reduction Act of 2022 (IRA), and it makes certain solar and wind projects eligible for an additional 10% to 20% ITC (total of 40% to 50% ITC). To be eligible for the Low-Income Bonus, ITC projects must be located in a low-income community, on Indian land or part of a qualified low-income residential building project or economic benefit project. The statute provides that the total projects eligible for the Low-Income Bonus in any year will be limited to 1.8 GW of direct current (DC) capacity, with the excess carried over to the following year. Accepted applicants will have four years from acceptance to place the property in service. The statute further provides that, within 180 days of the date of the enactment of the IRA (i.e., by February 12, 2023), the IRS must establish a program to allocate the annual 1.8 GW limitation to qualified facilities.
As required by the timeline set forth in the statute, the IRS issued the Notice this week with additional guidance regarding allocation of the annual capacity limitation. The Notice expressly confirms that the IRS will issue further guidance outlining specific application procedures, additional criteria, applicable definitions and other information necessary to submit an application for the Low-Income Bonus for the 2023 calendar year and that the procedure may be modified for the 2024 calendar year.
Acknowledging the goals of the Low-Income Bonus (including to increase adoption of and access to renewable energy facilities in low-income and other communities with environmental justice concerns, to encourage new market participants and to provide social and economic benefits to individuals and communities that have been historically overburdened with pollution, adverse human health or environmental effects and marginalized from economic opportunities), the Notice first confirms the allocation of the 1.8 GW capacity as follows:
- 700 megawatts (MW) for projects located in a low-income community
- 200 MW for projects located on Indian land
- 200 MW for projects that are part of a qualified low-income residential building project
- 700 MW for projects that are part of a qualified low-income economic benefit project.
The Notice also clarifies that subsequent guidance will incorporate additional criteria in determining how to allocate the foregoing four categories among eligible applicants. Those criteria may include a focus on facilities that (1) are owned or developed by community-based organizations and mission-driven entities, (2) have an impact on encouraging new market participants, (3) provide substantial benefits to low-income communities and individuals marginalized from economic opportunities and (4) have a higher degree of commercial readiness.
If the total applications for one of the four categories exceed the capacity for such category, then the IRS may use a lottery system or other process. Conversely, if the capacity in any category is not fully used in 2023, the excess may be reallocated by the IRS to another category to maximize the 2023 allocations. The Notice mentions that the awarded amount will neither exceed the DC capacity of the facility nor be prorated, suggesting that applicants will either be approved in full or rejected.
Importantly, the Notice clarifies that projects placed in service prior to being awarded an allocation by the IRS are not eligible to receive an allocation. This noteworthy restriction is not expressly stated in the statute and will be of interest to taxpayers considering the Low-Income Bonus for 2023 projects.
The application will be made by the owner of the project and can only be made with respect to one allocation category. The Notice provides that applicants that do not receive an allocation will be permitted to apply for future applications after calendar year 2023, however, it’s not clear if that means projects placed in service in 2023 could potentially claim allocations in 2024. Taxpayers losing out on capacity allocations in 2023 will not be placed on a waitlist, so they would have to reapply next year.
The Notice confirms that applications will be accepted in a phased approach during 2023, in 60-day application windows. The IRS anticipates that applications will be accepted for qualified low-income residential buildings and economic benefit projects in Q3 2023, and applications for low-income communities and Indian land will be accepted thereafter. Application guidance is forthcoming. The Notice also confirms that the US Department of Energy will provide administration services for the Low-Income Bonus, including reviewing applications, providing recommendations regarding the selection of applicants and performing the lottery or other applications process in the event there are more applicants than capacity. The Notice suggests that ultimate selection process will reside with the IRS, and accepted taxpayers will receive IRS notification of their acceptance. Finally, the Notice clarifies that an award of Low-Income Bonus capacity is not a determination that a project will qualify for the Low-Income Bonus or the ITC generally.
The Notice provides interesting insights into the IRS’s thinking on the Low-Income Bonus but leaves many questions unanswered, likely leaving the bonus largely outside the realm of transactions for the immediate future. For instance, while it clarifies four high-level allocation categories, the Notice also indicates that further considerations are forthcoming. Importantly, there is no certainty regarding how applicants will be chosen in the event any category is overcapacity. Accordingly, taxpayers meeting the technical requirements of the statute have no certainty regarding acceptance until further guidance is issued (or they receive notification from the IRS). Also of significance, the Notice fails to define what it means to be part of a qualified low-income residential building project or economic benefit project. While the other categories of eligible projects are well-understood under precedent law, qualified low-income residential building project and economic benefit project are new terms requiring IRS input. These projects could make up half of the Low-Income Bonus allocations in 2023, so it is imperative that the IRS provide further clarification as to their meaning.
Ultimately, it is not surprising that the Notice left so many questions unanswered as the IRA created a tremendous workload for the IRS. The statute expressly required the IRS to issue guidance on the Low-Income Bonus this week, but presumably the IRS is grappling with myriad other equally important regulatory questions stemming from the new law. Some of those questions arguably have much farther economic and statutory reach than the Low-Income Bonus (e.g., the prevailing wage and apprentice rules). Accordingly, it’s unsurprising that the IRS wouldn’t have time to do a sufficiently deep dive into the Low-Income Bonus on this short timeline and would effectively punt its regulatory obligation into Q3 2023.
We will be following the Low-Income Bonus in the coming months, including the release of any subsequent guidance. We will provide updates as they are made available.

Delaware Court Ruling Regarding Stockholder Class Vote Creates New Obstacle for Former SPACs (And What Companies Are Doing About It)
ARTICLE / CLIENT ALERT
Delaware Court Ruling Regarding Stockholder Class Vote Creates New Obstacle for Former SPACs (And What Companies Are Doing About It)
February 14, 2023
Read time: 7 min
In a case filed simply to determine whether a plaintiff was entitled to attorneys’ fees and expenses for conferring a benefit on a corporation, the Delaware Court of Chancery held that the planned stockholder vote by the corporation would have been insufficient under Delaware law to authorize amendments to the corporation’s certificate of incorporation in connection with a de-SPAC merger transaction. Garfield v. Boxed, Inc., No. 2022-0132-MTZ, 2022 WL 17959766 (Del. Ch. Dec. 27, 2022).
Since many special purpose acquisition companies (SPACs) with dual-class common stock utilized the same or a similar certificate of incorporation as the one at issue in Boxed, Inc., this ruling has thrown into question the validity of publicly traded shares of such companies. These companies are now rushing to the Delaware Court of Chancery with petitions for relief to avoid having their shares be deemed invalidly issued. Specifically, companies are seeking retroactive ratification of amendments to their certificates of incorporation (adopted in connection with their de-SPAC transactions) pursuant to Section 205 of the General Corporation Law of the State of Delaware (DGCL). Considering the wide-ranging consequences that the ruling in Boxed, Inc. can have, companies that went public by merging with a SPAC incorporated in Delaware should act quickly to assess whether their pre-de-SPAC certificate of incorporation has the same or similar language as the one at issue in Boxed, Inc. and determine whether they need to obtain relief in the form of court-approved ratification.
CASE FACTS AND HOLDING
Seven Oaks Acquisition Corp. (Seven Oaks), a Delaware corporation formed as a SPAC, had a certificate of incorporation (Charter) that authorized common stock, including Class A Common Stock and Class B Common Stock, and preferred stock. Seven Oaks was preparing to enter into a de-SPAC transaction via a merger with Boxed, Inc. To effectuate the merger, Seven Oaks needed to amend its Charter to increase the number of authorized shares of its Class A Common Stock and change the vote required to increase or decrease the number of authorized shares going forward. In order to amend the Charter, Seven Oaks sought a vote of the holders of Class A Common Stock and Class B Common Stock, voting together as a single class.
Prior to the vote, the plaintiff (a stockholder) sent a pre-suit demand to Seven Oaks’ board of directors (Board) insisting that the Board have the holders of Class A Common Stock vote on the amendments as a separate class from the holders of Class B Common Stock. The plaintiff contended that a separate class vote was required under the Charter and Section 242(b)(2) of the DGCL, which states that “[t]he holders of the outstanding shares of a class shall be entitled to vote as a class upon a proposed amendment, whether or not entitled to vote thereon by the certificate of incorporation, if the amendment would increase or decrease the aggregate number of authorized shares of such class . . . or alter or change the powers, preferences, or special rights of the shares of such class so as to affect them adversely.” After receiving this pre-suit demand, Seven Oaks sought and obtained a separate class vote of the holders of Class A Common Stock.
The plaintiff then filed suit seeking attorneys’ fees and expenses for the corporate benefit he conferred on Seven Oaks. Seven Oaks argued that the plaintiff was not entitled to attorneys’ fees and expenses because a separate class vote was not necessary under the Charter or the DGCL since the Class A Common Stock was a series of the common stock, not a separate class of stock.
On motions for summary judgment, the principal issue before the Delaware Court of Chancery was whether the Class A Common Stock was a class of stock or a series of a class of stock because, absent a class vote opt-out in the Charter (pursuant to Section 242(b)(2) of the DGCL), a class of stock is entitled to vote on amendments that increase or decrease the number of authorized shares of such class of stock.
The Delaware Court of Chancery interpreted the Charter as creating the Class A Common Stock as a class of stock rather than a series of the common stock class. The Court concluded this because the Charter (1) used the word “class,” instead of “series,” to describe the authorized common shares; (2) listed the total number of shares of all classes of stock and then the number and par value of shares of each class of stock, in accordance with Section 102(a)(4) of the DGCL, but also separately listed the number and par value of shares of each of the Class A Common Stock and Class B Common Stock, which the Court viewed as evidence that the Charter was designed to authorize statutorily compliant classes; and (3) authorized the Board to create one or more series of preferred stock and establish the number of shares to be included in each series of preferred stock by resolution of the Board but did not vest the Board with the same authority to fix or grant series of the common stock. Based on this, the Court awarded the attorneys’ fees and expenses for the plaintiff, holding that the plaintiff conferred a meaningful corporate benefit on Seven Oaks and its stockholders by causing the Board to seek and obtain a separate class vote of the Class A Common Stock, without which the additional authorized shares of Class A Common Stock would have been invalidly issued.
THE FALLOUT
The holding in Boxed, Inc. has caused publicly traded companies that previously merged with a SPAC incorporated in Delaware that had a certificate of incorporation with the same or a similar dual-class common stock structure as the Charter of Seven Oaks to question the validity of their publicly traded shares, which could have both significant direct and indirect adverse consequences, including relating to public company reporting obligations.
Fortunately, the DGCL affords corporations a path to retroactively fix defective corporate acts, such as an invalid stock issuance, either pursuant to the self-help ratification process authorized by Section 204 of the DGCL or the court-approved ratification process authorized by Section 205 of the DGCL. Some companies impacted by Boxed, Inc. have opted for the court-approved ratification process—by petitioning the Delaware Court of Chancery for relief—because of the speed and certainty afforded by this process. When determining whether to validate a defective corporate act, the court may consider factors it deems just and equitable, including whether any person will be harmed by the failure to ratify or validate the defective corporate act.
TAKEAWAYS
- Any company that merged with a SPAC incorporated in Delaware should review its pre-de-SPAC certificate of incorporation to determine whether it was similar to the one at issue in Boxed, Inc.
- If similar, the company should then determine whether it sought and obtained a separate class vote to increase the number of authorized shares of common stock in connection with the de-SPAC transaction.
- Even if a separate class vote was not sought, the company should determine whether a separate class vote was actually obtained as a result of having a sufficient number of shares of each class voting in favor of the amendment to the certificate of incorporation, notwithstanding not holding a separate vote or disclosing that such a separate class vote was being sought.
- If the separate class vote was actually obtained, the company should consult with its legal counsel to determine if further action must be taken to determine if the publicly traded shares were validly issued.
- If uncertainty remains as to the validity of the company’s issued shares, the company should consult with its legal counsel to determine if ratification is warranted, either by the self-help ratification process or the court-approved ratification process.
Should you have any questions regarding the impact of this holding, please contact one of the authors of this article or your regular McDermott lawyer.
Digital Health: 2022 Annual Report
ARTICLE / REPORT
Digital Health: 2022 Annual Report
February, 2023
Read time: 2 min
Digital health is one of the fast-growing segments of the healthcare market, with patients, clinicians and regulators increasingly aligned behind the opportunities that digitization presents. Moving into 2023 federal and state regulators are setting new standards for telehealth and digital care in a post-public health emergency world. On a transactional front, slowdown and stagnation is expected as economic headwinds impact dealmaking in all industries, but the outlook remains brighter for digital health companies offering transformative solutions.
Our Digital Health team takes a close look at the forces shaping the sector in 2023, including:
- Telehealth Regulatory Trends
- Women’s Health
- Increased Scrutiny on Tracking, Privacy and Security
- Unwinding from the Public Health Emergency
- State of Investing and Dealmaking

The Joint Commission Eliminates 14% of Its Standards Across All Accreditation Programs
ARTICLE / CLIENT ALERT
The Joint Commission Eliminates 14% of Its Standards Across All Accreditation Programs
February 13, 2023
Read time: 6 min
Effective January 1, 2023, The Joint Commission (TJC) eliminated 168 (or 14%) of its accreditation standards across all of its accreditation programs and revised 14 other standards. To further streamline its standards, TJC is expected to announce a second tranche of eliminated or revised TJC standards in June 2023.
The Joint Commission (TJC) accredits a variety of healthcare organizations, including hospitals, critical access hospitals, ambulatory care organizations and laboratories. Many TJC-accredited healthcare organizations also rely on their TJC accreditation for “deemed compliance” with federal and state administrative agencies’ requirements for certifications or licenses without the need for separate survey. TJC’s announcement of a major reduction in its accreditation standards is especially welcomed by those healthcare organizations that achieve several regulatory authorizations through TJC accreditation.
In September 2022, TJC announced that it would review its accreditation requirements that go above and beyond the Centers for Medicare and Medicaid Services’ (CMS) Conditions of Participation or Conditions for Coverage (collectively, CoPs). In that announcement, TJC acknowledged that the stress of the COVID-19 pandemic on accredited healthcare providers was its motivation to focus on streamlining standards and decreasing administrative burdens so that only the strategies and structures that support patient safety, quality and equity are required.
Specifically, TJC assessed each of the “above and beyond” requirements that did not directly correspond to a CoP by considering whether the requirement addressed an important quality and safety issue, was redundant, or otherwise required time and resources to comply that exceeded the estimated benefit to patient care and health outcomes.
TJC also conducted quantitative analyses of scoring patterns, tests for redundancy, literature reviews, field reviews and engaged experts within the field to determine which of the implicated requirements could be eliminated or revised. CMS approved the eliminated and revised standards.
January 2023 Eliminations and Revisions
Below are links to the deleted or revised standards, effective January 1, 2023, in the order of greatest to least amount of change. Also included is a list of the implicated chapters that have deleted standards and a reference to the revised standards:
- Hospitals
- Hospital: 56 deleted and four revised
- Deleted standards implicate the following 11 chapters of TJC’s Hospital Accreditation Program: (i) Environment of Care, (ii) Human Resources, (iii) Information Management, (iv) Leadership, (v) Life Safety, (vi) Medication Management, (vii) National Patient Safety Goals, (viii) Provision of Care, Treatment, and Services, (ix) Performance Improvement, (x) Rights and Responsibilities of the Individual, and (xi) Waived Testing.
- Revised: (i) Leadership Standard (Standard LD) 02.02.01 and its Elements of Performance (EP) 1-3, and (ii) Standard Waived Testing (Standard WT) .02.01.01, EP1.
- Critical Access Hospital: 37 deleted and four revised
- Deleted standards implicate the following 11 chapters of TJC’s Critical Access Hospital Accreditation Program: (i) Environment of Care, (ii) Human Resources, (iii) Information Management, (iv) Leadership, (v) Life Safety, (vi) Medication Management, (vii) National Patient Safety Goals, (viii) Provision of Care, Treatment, and Services, (ix) Performance Improvement, (x) Rights and Responsibilities of the Individual, and (xi) Waived Testing.
- Revised: (i) Standard LD02.02.01 and EPs 1-3, and (ii) Standard WT.02.01.01, EP1.
- Hospital: 56 deleted and four revised
- Ambulatory Care
- Ambulatory Health Care: 20 deleted and one revised
- Deleted standards implicate the following nine chapters of TJC’s Ambulatory Health Care Accreditation Program: (i) (i) Environment of Care, (ii) Human Resources, (iii) Information Management, (iv) Leadership, (v) Life Safety, (vi) Medication Management, (vii) National Patient Safety Goals, (viii) Performance Improvement, and (ix) Waived Testing.
- Revised: Standard WT.02.01.01, EP 1.
- Office-Based Surgery: 18 deleted and one revised
- Deleted standards implicate the following six chapters of TJC’s Office-Based Surgery Accreditation Program: (i) Environment of Care, (ii) Human Resources, (iii) Leadership, (iv) Medication Management, (v) National Patient Safety Goals, Performance Improvement, and (vi) Waived Testing.
- Revised: Standard WT.02.01.01, EP1.
- Home Care: 10 deleted and one revised
- Deleted standards implicate the following six chapters of TJC’s Home Care Accreditation Program: (i) Environment of Care, (ii) Leadership, (iii) Life Safety, (iv) Medication Management, (v) Provision of Care, Treatment, and Services, and (vi) Waived Testing.
- Revised: Standard WT.02.01.01, EP1.
- Behavioral Health Care and Human Services: Nine deleted and one revised
- Deleted standards implicate the following four chapters of TJC’s Behavioral Health Care and Human Services Accreditation Program: (i) Leadership, (ii) Life Safety, (iii) Medication Management, and (iv) Waived Testing.
- Revised: Revised: Standard WT.02.01.01, EP1.
- Ambulatory Health Care: 20 deleted and one revised
- Nursing Care Center: 12 deleted and one revised
- Deleted standards implicate the following six chapters of TJC’s Nursing Care Center Accreditation Program: (i) Life Safety, (ii) Medication Management, (iii) National Patient Safety Goals, (iv) Provision of Care, Treatment, and Services, (v) Performance Improvement, and (vi) Waived Testing.
- Revised: Please note that the current TJC prepublication does not reflect the revised standard.
- Laboratory Services: Six deleted and one revised
- Deleted standards implicate the following four chapters of TJC’s Laboratory Accreditation Program: (i) Environment of Care, (ii) Human Resources, (iii) Leadership, and (iv) Waived Testing.
- Revised: Revised: Standard WT.02.01.01, EP1.
Constant Change
According to TJC’s President and CEO, Dr. Jonathan Perlin, TJC plans to keep reviewing its standards every six months to ensure performance measures are relevant to quality improvement. TJC is expected to announce a second tranche of eliminated or revised TJC standards in June 2023. Healthcare organizations should consult with internal and external resources to review the changes and assess how to update current operations and compliance efforts to ensure they are current with the new standards. Also on the horizon for hospitals and critical access hospitals, as explained in this On the Subject article, is TJC’s certification program for Health Care Equity with newly revised quality measures effective July 1, 2023.


